← All trials
NCT04724044
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 25, 2021
- Primary completion
- Jan 24, 2023
- Completion date
- Apr 20, 2023
- First posted
- Jan 26, 2021
- Last posted
- Jun 22, 2021
- Enrollment
- 278
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hellenic Institute for the Study of SepsisLead sponsor
- Hellenic Sepsis Study GroupStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.